NASDAQ: KNSAKiniksa Pharmaceuticals International PLC Stock
$28.30+0.57 (+2.06%)
Updated Jun 13, 2025
KNSA Price
$28.30
Fair Value Price
N/A
Market Cap
$2.07B
52 Week Low
$17.38
52 Week High
$30.69
P/E
-117.92x
P/B
4.51x
P/S
3.35x
PEG
N/A
Dividend Yield
N/A
Revenue
$481.17M
Earnings
-$16.95M
Gross Margin
85.8%
Operating Margin
-1.31%
Profit Margin
-3.5%
Debt to Equity
0.31
Operating Cash Flow
$44M
Beta
0.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KNSA Overview
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KNSA's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KNSA
Ranked#32 of 464
Ranked#32 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important KNSA news, forecast changes, insider trades & much more!
KNSA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KNSA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KNSA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KNSA is good value based on its book value relative to its share price (4.51x), compared to the US Biotechnology industry average (4.66x)
P/B vs Industry Valuation
KNSA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more KNSA due diligence checks available for Premium users.
Valuation
KNSA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-117.92x
Industry
-108.97x
Market
31.36x
KNSA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.51x
Industry
4.66x
KNSA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KNSA's financial health
Profit margin
Revenue
$137.8M
Net Income
$8.5M
Profit Margin
6.2%
KNSA's Earnings (EBIT) of -$6.31M... subscribe to Premium to read more.
Interest Coverage Financials
KNSA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$599.3M
Liabilities
$141.8M
Debt to equity
0.31
KNSA's short-term assets ($355.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KNSA's short-term assets ($355.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KNSA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KNSA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$22.3M
Investing
-$51.5M
Financing
$2.8M
KNSA's operating cash flow ($44.03M)... subscribe to Premium to read more.
Debt Coverage Financials
KNSA vs Biotech Stocks
Kiniksa Pharmaceuticals International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.